Kornimate/medical-research-clean huggingface dataset:
autologous oral mucosa transplantation for limbal stem cell deficiency

Conditions: Limbal Stem-cell Deficiency

Summary: purpose: to report clinical and histochemical results of oral mucosa graft transplantation in eyes with limbal stem cell deficiency. design: prospective observational study. methods: 32 eyes of 27 patients with limbal stem cell deficiency underwent direct oral mucosa graft transplantation with amniotic membrane transplantation with a mean follow-up of 19 months. clinical course of the disease including emergency surgeries, planned curative procedures, conjunctival inflammation, acute inpatient treatment and best corrected visual acuity were assessed at 3 months postoperatively and at last follow up visit. the unneeded parts of oral mucosa graft were analyzed immunohistochemically with staining for mesenchymal stem cell markers and pericytes (cd 90, cd 146, cd 166, cd 31, cd 68, protein gene product).


Eligibility criteria:
inclusion criteria: * limbal stem cell deficiency at least in one eye * undergoing oral mucosa with amniotic membrane transplantation * obtained written informed consent exclusion criteria: * no written informed consent

Keywords: limbal stem-cell deficiency oral mucosa transplantation amniotic membrane mesenchymal stem cells
a 3-year, prospective, non-interventional, multicenter registry in sickle cell disease (scd) patients

Conditions: Sickle Cell Disease

Summary: a long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.


Eligibility criteria:
inclusion criteria: * male or female patients with hbss, hbs/beta-thalassemia and hbsc * age \> 2 years old. * written informed consent by the patient or legal guardians, and pediatric assent where indicated. exclusion criteria: * patients with sickle cell trait (hbas) are not eligible for the study * patient or legal guardians unable or unwilling to give consent, or pediatric assent where indicated.

Keywords: sickle cell disease iron over load
dynamic arterial elastance as a predictor of arterial blood pressure response to fluid administration in septic patients

Conditions: Sepsis

Summary: correction of arterial hypotension is essential for adequate cellular metabolism. maintaining map above a minimum level has been recommended in order to prevent further tissue hypoperfusion and organ dysfunction.functional assessment of arterial load by dynamic arterial elastance (eadyn), has recently been shown to predict the arterial pressure response to volume expansion (ve) in hypotensive, preload-dependent septic patients.

after approval from the ethics and research committee of faculty of medicine, cairo university, an informed consent will be obtained from each patient's next of kin. arteial cathter will be inserted in radial artery and connected through an arterial line to invasive arterial blood pressure monitor. electrical cardiometry will be attached to patient through the placement of four skin sensors on the neck and left side of the thorax12. a set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (fc) of 150-250 ml normal saline over 5-10 minutes.fluid-responders are patients with a sv increase ≥10% after fluid challenge (fc).

Eligibility criteria:
inclusion criteria: * adult patients (more than 18 years). * sepsis as a cause of admission. exclusion criteria: * • patients younger than 18 years of age. * pregnant females. * trauma as a cause of intensive care unit (icu)admission. * known medical history of vasodilator therapy. * cardiac arrhythmias. * any absolute contraindication for fluid administration such as congestive heart failure, pulmonary edema and/or fluid overload
efficacy study of tamsulosin and tolterodine treatment for chronic prostatitis

Conditions: Prostatitis

Summary: the purpose of this study is to determine whether tamsulosin and tolterodine are effective in the treatment of men with lower urinary tract symptoms and chronic prostatitis/chronic pelvic pain syndrome.

chronic prostatitis/chronic pelvic pain syndrome (cp/cpps) is a common disorder in urological clinics. most of the clinically cp/cpps are to some extent associated with storage (irritative) symptoms, such as increased frequency, urgency, and nocturia, namely many patients with cp/cpps have overactive bladder symptoms. alpha-blocker therapy has been advocated as a treatment modality for cp/cpps. some trials showed a statistically and likely clinically significant treatment effect, while other trials showed no benefit. therefore, tamsulosin combination with tolterodine treatment for cp/cpps may be more effective than tamsulosin single.

Eligibility criteria:
inclusion criteria: 1. diagnosis of cp/cpps based on the classification of us national institutes of health, aged 18-45 years 2. total score of at least 12 on the national institutes of health chronic prostatitis symptom index (nih-cpsi) 3. urinary score of at least 4 on the cpsi 4. subjects who anticipate improving symptoms exclusion criteria: 1. previous treatment with any other alpha-adrenergic receptor blocker and antimuscarinic agents for symptoms of cp/cpps or for any other reason 2. those who had had previous urinary tract infection with the last year 3. those who had been treat or were taking medication that could affect lower urinary tract function 4. those who met the criteria for chronic bacterial prostatitis after lower urinary tract localization studies 5. those who had other significant medical problems

Keywords: prostatitis adrenergic alpha-antagonists tolterodine
heavy menstrual bleeding and iron deficiency anemia

Conditions: Heavy Menstrual Bleeding

Summary: in the present study, we test the ability of amss as a simple tool to identify women with hmb who have id/ ida. we will compare the amss score to patients' hemoglobin and serum ferritin in women with self-reported hmb and women with normal menstrual flow.

anemia remains a critical health burden in low- and middle-income countries (lmics) and a paradigm shift is needed to effectively reduce the prevalence in women. the reproductive years place women at high risk of anemia in general, and iron deficiency anemia (ida) in particular, largely because of menstrual and delivery -associated blood loss, as the lost iron is often not adequately replenished from dietary sources. iron deficiency, even without anemia, has profound adverse effects on multiple cellular and metabolic parameters and frequently manifests with impaired cognitive and physical function. in africa and eastern mediterranean regions, around 39% of non-pregnant women and 40-45% of pregnant women have anemia as estimated by the world health organization (who). maternal anemia is a risk factor for preterm labor and both maternal and neonatal morbidity and mortality. although data is limited, 5-28% of women in lmics experience abnormal uterine bleeding (aub) yet the importance of menstrual blood loss as an indicator of and a risk factor for anemia is frequently ignored in anemia control and prevention strategies. the condition is further complicated by the fact that both women and their physicians tend to normalize menstrual symptoms. to enable development of comprehensive interventions to address ida among women in our locality, it is critical to characterize heavy menstrual bleeding (hmb) and its relationship with ida among women and determine ways to use these data to direct women at risk for ida to appropriate healthcare services for evaluation and treatment. for women with hmb, early diagnosis and treatment of anemia is important to prevent its negative health consequences. however, in low resource settings, laboratory facilities are not always available. in addition, laboratory tests may be expensive limiting their use in such circumstances. for this reason, a cheap, simple to use tool to identify women at high risk of anemia who require further evaluation and treatment is needed. the aberdeen menorrhagia severity scale (amss) is a multi-dimensional scale. it measures quality of life in women with hmb in addition to menstrual bleeding characteristics. amss consists of 13 questions. with a 4-point answer to each question. maximum score is 47, which is converted to a percentage. the lower the scale is associated with better quality of life. the amss has been validated against the sf-36, which is a generic scale for measurement of quality of life.

Eligibility criteria:
inclusion criteria: * reproductive age women, above age of 18 years old. exclusion criteria: * women with amenorrhea, postmenopausal women, current or past (in last 6 months) users of hormonal contraceptives, women who have delivered in the past year, or breast fed in past 6 months are all excluded from the study
study evaluating the effect of jublia on dermatophytomas

Conditions: Onychomycosis; Dermatophytosis

Summary: this study will examine how jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.

dermatophytomas are known to be resistant to even long courses of systemic antifungals, and have therefore been excluded from both topical and systemic clinical trials for onychomycosis, including those for efinaconazole solution. efinaconazole (jublia) 10% solution is an fda approved topical medication indicated for treatment of distal lateral subungual onychomycosis (dlso), and the utility of this medication likely exceeds published results. efinaconazole solution's novel ability to penetrate into the subungual space likely accounts for improved treatment results seen in dlso treated with jublia. we will investigate the utility of topical efinaconazole solution in the treatment of dermatophytomas.

Eligibility criteria:
inclusion criteria: * has the informed consent been signed and patient's questions answered. * age \>= 18 * patient willing and able to participate for the full duration of the study * no onychomycosis * greater than 4 weeks from prior major surgery for any indication * willing to abstain from: the application of other topical medications or cosmetic products to the toenail professional pedicures for the duration of the study. - females of childbearing potential must: have been using adequate contraception (abstinence, intrauterine device (iud), birth control pills or spermicidal gel with diaphragm or condom) since their last menses agree to continue using adequate means of contraception (abstinence, iud, birth control pills or spermicidal gel with diaphragm or condom) for the duration of study participation females are not considered to be of childbearing potential if they are at least 1 year postmenopausal or have had a tubal ligation, bilateral oophorectomy or hysterectomy. exclusion criteria: * active onychomycosis of the toenails or fingernails * any of the following in the 4 weeks (or as indicated) prior to randomization: major surgery for any indication - any personal history of: invasive cancer diagnosed or treated within the past 5 years. participants who have been in remission for 5 years or more and have not required treatment in the past 5 years may be eligible if the principal investigator believes there is little to no risk of recurrence. * concurrent use of the following medications or treatments other topical antifungals for any concomitant infection * females who are pregnant or lactating. should a woman become pregnant or suspect she is pregnant while she is participating in this study she should notify the study physician immediately. * uncontrolled concurrent illness including ongoing or active infection, psychiatric illness/social situations that would limit compliance with study requirements or other underlying serious medical condition which, in the investigator's opinion, might preclude study participation.
clinical post-operative assessment of chronic signs & symptoms related to infected primary molars after using rotary versus manual systems in cleaning the root canals

Conditions: Chronic Infection

Summary: one of the most important concerns in pediatric dentistry is the loss of necrotic primary molars leading to space loss. pulpectomies for primary teeth with severe pulpal involvement should be considered as the treatment of choice. bacteria plays an essential role in the initiation and perpetuation of pulpal and periapical disease. the investigator's target when cleaning and shaping the root canal system is to remove bacteria-containing tissue. the removal of organic debris is the main purpose of instrumentation in pulpectomy procedures in primary teeth, this could be achieved using manual or rotary ni-ti files. a practical pulpectomy technique for the primary teeth should include the following:1) fast procedure with short treatment time and minimal number of appointments.2) effective debridement of the root canal without weakening the tooth structure or endangering the underlining permanent teeth.3) minimal procedural complications. 4) maintaining tooth function until it is naturally exfoliated. manufacturers using rotary files highlight their cleaning efficiency for root canal preparations, simple procedures, and decreased procedure time, which is especially important in children. considering that preparation time is an important clinical factor in pediatric patient management, the use of rotary instruments for pulpectomies in primary teeth is recommended.


Eligibility criteria:
inclusion criteria: * primary molars with fistula / chronic abscess * teeth which if lost possibility of space maintainer construction exists * pre-operative radiograph showing absence of severe root resorption exclusion criteria: * teeth with non-restorable crowns * expected shedding time within one year

Keywords: rotary instrumentation pulpectomy primary teeth
mobile health device study for myeloma patients

Conditions: Multiple Myeloma; Myeloma

Summary: enrolled participants health status will be tracked by using a mobile health-monitoring device while undergoing chemotherapy for multiple myeloma.

newly diagnosed multiple myeloma participants receiving induction chemotherapy will be continuously bio-monitored at baseline (1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles using the garmin vivofit wearable device. for those patients continuing with asct, patients will be bio-monitored up to 90 days post asct. the study will include a total of 40 newly diagnosed multiple myeloma participants in two cohorts with 20 patients in each cohort (cohort a and b). cohort a will be comprised of patients \ /= 65 years.

Eligibility criteria:
inclusion criteria newly diagnosed multiple myeloma meeting international myeloma working group (imwg) criteria (as below) participants with clinical and histological confirmation of diagnosis planning to receive chemotherapy are eligible: * newly diagnosed multiple myeloma patients will have evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following: * hypercalcemia: serum calcium \>0.25 mmol/l (\> 1 mg/dl) above upper limit of normal or ≥ 2.75 mmol/l (11 mg/dl) * anemia: hemoglobin value \ 2 g/dl below lower limit of normal * bone disease: ≥ 1 lytic lesions on skeletal x-ray, ct, or pet-ct. for patients with 1 lytic lesion, bone marrow should demonstrate ≥ 10% clonal plasma cells * clonal bone marrow plasma cell percentage ≥ 60% * involved/un-involved serum free light chain ratio ≥100 and involved free light chain \>100 mg/l * \> 1 focal lesion on magnetic resonance imaging study (lesion must be \>5 mm) in size * all study participants will be required to receive primary chemotherapy treatment at a memorial sloan kettering facility, including regional outpatient sites. * all study participants will be required to have a smart phone or tablet device compatible with the garmin vivofit device. exclusion criteria * plasma cell leukemia * poems syndrome * amyloidosis

Keywords: multiple myeloma garmin vivofit
evaluation of a simple pharmacokinetic tool (mypkfit™) to guide personalized factor viii dosing in patients with hemophilia

Conditions: Hemophilia A

Summary: this is an investigator-initiated, industry-funded, multi-centre, international study that will be carried out prospectively at hemophilia treatment centres across canada, the czech republic and australia with sickkids as the coordinating site. the study will use a central laboratory not directly affiliated with any of the participating sites. enrollment target is 50 participants, both adult and pediatric with severe hemophilia a receiving advate, who will each complete a 2-point and 6-point pharmacokinetic (pk) sampling. the main aim is to compare the results of a 2 sample pk using clinically practical time points and mypkfit™ (a web-based, population pk bayesian tool) to a 6 sample population pk to determine whether the results obtained are in good agreement.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of hemophilia a; * severe disease (fviii \<2%); * receiving advate for prevention of bleeding (prophylaxis) or receiving advate on demand and a candidate for prophylaxis; * body weight ≤120 kg; and ≥12kg; exclusion criteria: * fviii inhibitor positive (level of ≥0.6 bethesda units \[bu\] per ml using the nijmegen modification of the bethesda assay). inhibitor status to be documented as negative prior to study enrollment according to the two most recent, consecutive inhibitor assays on record. if patients have \< 50 exposure days, an assay will be completed centrally within a reasonable timeframe (approximately 8 weeks suggested) to make sure that they are negative. * body weight \>120 kg or \<12kg; * human immunodeficiency virus (hiv) positivity with cluster of differentiation 4 (cd4) count \< 200 / microliter; * significant hepatic dysfunction, alanine aminotransferase (alt) or aspartate aminotransferase (ast) \>5 times upper limit of normal * history of recent events that might affect fviii half-life (e.g., infection, surgery or an invasive procedure) within 2 weeks of blood sampling.

Keywords: hemophilia a pharmacokinetics mypkfit
uterine artery and spiral artery doppler parameters in patients with postmenopausal bleeding

Conditions: Postmenopausal Bleeding

Summary: this study was to investigate the diagnostic value of ultrasonography and blood flow measurements in uterine arteries and spiral arteries by transvaginal color doppler ultrasonography in the detection of the endometrial pathology in women with postmenopausal bleeding.

this prospective cross-sectional observational study will be conducted at the department of obstetrics and gynecology, banha university, egypt during the period starting from january 2014. the study protocol will be approved by the local ethics committee and written informed consent will be obtained from each patient before the study commenced. seventy patients with postmenopausal bleeding will be included in the study after verbal consent. they will be recruited from patients attending gynecologic clinic in banha university hospital. all patients will be subjected to the following: for all included women the following will be done: 1. full history taking. 2. complete general, abdominal, and local examination. 3. ultrasonographic assessment of the uterus all data were performed for all patients in the lithotomy position after they had emptied their bladder using a 7.5 megahertz transducer by a single operator. 1. using colour doppler in the 2d mode, flow velocity waveforms were obtained from the ascending main branch of the uterine artery on the right and left side of the cervix in a longitudinal plane before they entered the uterus. 2. the gate of the doppler was positioned when the vessel with good colour signals was identified on the screen. pulsatility index of the uterine arteries were calculated electronically when similar consecutive waveforms of good quality were obtained and the averaged uterine pi. pulsatility index (pi): this index, also known as the mean pulsatility index, to distinguish it from the peak to peak pulsatility index, is expressed by: pi= (s-d) / mean where s is the peak systolic velocity, d is the end diastolic velocity and velocity is the time averaged maximum velocity over the cardiac cycle (1). 3. blood flow velocity waveforms were evaluated in the spiral arteries at the sub endometrial region that is within 1 mm of the originally defined myometrial-endometrial contour (2). histopathological diagnosis of endometrium obtained by biopsy is the gold standard for diagnosis.

Eligibility criteria:
inclusion criteria: 1. endometrial thickness ≥ 5 mm measured by two-dimensional transvaginal ultrasound. 2. pap smear is negative for malignancy. exclusion criteria: 1. postmenopausal woman on hormon replacement therapy. 2. trans-vaginal examination not possible (vaginal stenosis or patient refusing trans-vaginal ultrasound). 3. adnexal pathology. 4. general causes of bleeding e.g: hemophilia , anticoagulation therapy
methylene blue intra-vital nerve staining

Conditions: Neurologic Findings

Summary: in previous studies, we know methylene blue (mb) stains nerves, and oxidized mb has near-infrared (nir) fluorescence for fluorescent observation. in this trial we using mb on human skin and combining mb and third-harmonic generation imaging (thg) to label cutaneous nerve fibers.

intravital images were obtained before injection and then taken at 0.5, 1, 1.5, 2, 2.5, and 3 h after intradermal 0.03% (0.3 mg/ml, 1500μm) mb (10mg/ml "astar") injection using a 0.5-ml 29-gauge insulin syringe needle (becton, dickinson and company, usa). the participant lay down and the skin was imaged 10 cm above the ankle in the lower leg and above the wrist in the middle forearm; three sites in each limb were randomly selected for each time point. shg or thg captured mb signals with two-photon excitation microscope at the molecular biomedical imaging research center of national taiwan university.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * used serotonin agonist medication
study trial of dexamethasone use for alleviation of symptoms after scleral buckle eye surgery

Conditions: Retinal Detachment

Summary: dexamethasone is a medication that has been shown to have clear anti-nausea, anti-inflammatory, and painkilling properties. dexamethasone is currently used to manage postoperative symptoms of a variety of surgical procedures. however, its effect has not been validated for scleral buckling surgery, which is used to treat retinal detachment, a medical emergency that can lead to permanent blindness. in this study, the investigators will randomly administer dexamethasone to half of scleral buckling surgery patients, and a placebo to the other half. the investigators will then compare the postoperative symptoms of the two groups in order to determine whether dexamethasone should be used for scleral buckling surgeries.


Eligibility criteria:
inclusion criteria: * age 18-79 years old * scheduled for scleral buckle surgery to treat a retinal detachment * consent to participate in study exclusion criteria: * pregnant or nursing * prior treatment with steroids * severe diabetes mellitus (hba1c \> 8%) * use of opioids, sedatives, or any kind of analgesics \<1 week before scleral buckling surgery * history of alcohol or drug abuse

Keywords: scleral buckling dexamethasone post-operative nausea and vomiting
part vs whole task mastery training for laparoscopic hernia repair

Conditions: Hernia

Summary: the investigators will perform a randomized controlled trial with a stratified-block design to compare the effect of the part versus whole task simulation training for tep repairs.


Eligibility criteria:
inclusion criteria: * study participants: only residents who have achieved mastery of the tep training curriculum (in either arm) will be eligible for or assessment * patients: all patients deemed fit by the staff supervising surgeon to undergo a tep repair will be considered for this study.

Keywords: mastery learning surgical education laparoscopic hernia repair part vs whole task contextual interference laparoscopy training curriculum